CASPIAN: Phase III Study of First-line Durvalumab + Tremelimumab + EP vs Durvalumab + EP vs EP Alone in Extensive-Stage SCLC

May 29-31, 2020; Online at meetings.asco.org/am
Updated analysis finds durvalumab + EP maintains significant OS improvement vs EP alone with no further benefit with addition of tremelimumab.
Format: Microsoft PowerPoint (.ppt)
File Size: 455 KB
Released: June 1, 2020

Acknowledgements

Provided by Clinical Care Options, LLC.

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by educational grants from
AstraZeneca
Daiichi Sankyo, Inc.
Ipsen Biopharmaceuticals, Inc.
Jazz Pharmaceuticals, Inc.
Merck Sharp & Dohme Corp.

Related Content

In this slideset from Clinical Care Options (CCO), experts provide insights on the optimal use of CAR T-cell therapy for lymphomas

person default Caron A. Jacobson, MD Released: June 16, 2021

In this slideset from Clinical Care Options (CCO), experts provide insights on CAR T-cell strategies for myeloma

Noopur Raje, MD Released: June 16, 2021

In this slideset from Clinical Care Options (CCO), experts provide insights on the optimal use of CAR T-cell therapy for ALL

Jae H. Park, MD Released: June 16, 2021

Download these expert-selected slides covering current recommendations on evaluating and treating patients for NTRK fusion-positive cancer, from Clinical Care Options (CCO).

George D. Demetri, MD Alexander Drilon, MD Theodore Laetsch, MD Released: June 16, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue